NeoGenomics, Inc.
NEOHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeNeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company carries a $1.90B market cap, placing it firmly in the small-cap category. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Market Cap
$1.90B
Beta
1.74
P/E (TTM)
—
P/E (Fwd)
40.08
EPS (TTM)
$-0.76
EPS (Fwd)
$0.36
ROE
-11.6%
ROA
-2.6%
Cash
$146.1M
Total Debt
$408.5M
Free CF
$33.2M
52W Change
134.1%
Annual Financials
Cash vs Debt
On the balance sheet, NEO has $146.1M in cash with $408.5M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $33.2M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -11.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $509.7M (2022) to $727.3M (2025), reflecting a 43% increase over the period.
With a beta above 1.5, NEO tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for NeoGenomics, Inc. and its sector.